The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill
  
The Section 232 investigation gives generic manufacturers an opportunity to highlight supply chain vulnerabilities. (Shutterstock)

More from Supply Chain

More from Leadership